查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953948

抗菌藥物抗藥性監測市場－全球產業規模、佔有率、趨勢、機會及預測（按解決方案、應用、最終用戶、地區和競爭格局分類，2021-2031年）

Antimicrobial Resistance Surveillance Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Solution, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球抗生素抗藥性監測市場預計將從 2025 年的 65.4 億美元成長到 2031 年的 92.7 億美元，複合年成長率為 5.98%。

該領域包括專門的診斷設備和軟體平台，旨在系統地追蹤和分析病原體對抗菌藥物的反應。推動這一成長的關鍵因素包括：迫切需要應對多重抗藥性細菌的日益增多，以及全球嚴格執行抗菌藥物管理計畫。此外，政府積極採取措施並投入資金，旨在加強檢查室基礎設施建設並確保數據相容性，這也加速了這些關鍵監測系統在醫療網路中的應用。

市場概覽
預測期 2027-2031
市場規模：2025年 65.4億美元
市場規模：2031年 92.7億美元
複合年成長率：2026-2031年 5.98%
成長最快的細分市場 診斷試劑盒
最大的市場 北美洲

儘管取得了這些進展，但實施和維護先進監測技術的高成本仍然是一大障礙，阻礙了其在資源匱乏地區的廣泛應用。這種資金限制往往阻礙了缺乏足夠技術基礎設施的發展中地區廣泛採用自動化報告功能。世界衛生組織（世衛組織）表示，到2025年，已有127個國家正式加入全球抗菌藥物抗藥性和使用監測系統（GAMURS），以支持標準化監測舉措，但成本障礙仍然是普遍實施的一大挑戰。

市場促進因素

多重抗藥性感染疾病的日益普遍是全球抗菌藥物抗藥性監測市場的主要促進因素，也因此迫切需要擴展診斷能力。隨著病原體對標準療法產生抗藥性的速度加快，醫療系統面臨著實施能夠即時檢測抗藥性模式的先進監測框架的壓力。這種日益嚴重的生物威脅推動了對高通量系統的需求，以支持經驗性治療和控制策略。根據2024年9月發表在《採血針》上的一項系統性分析，預計2025年至2050年間，細菌抗菌藥物抗藥性將導致全球超過3900萬人直接死亡，這迫使診斷技術開發商優先開發能夠識別新型抗藥性標誌物的技術，以減輕預計的死亡負擔。

第二個關鍵促進因素是公共和私人部門加大對抗菌素抗藥性監測和基礎設施的投入，這直接解決了建構全面監測網路的高成本。各國政府和國際組織正積極資助檢查室現代化改造，以填補人類、動物和環境健康的數據空白。例如，英國政府於2024年5月宣布了一項8,500萬英鎊的資助計劃，用於支持國際合作，包括加強加勒比海和非洲的監測工作。儘管進行了這些投資，挑戰依然存在。全球老化聯盟2024年2月發布的報告顯示，在分析的11個高所得國家中，只有4個國家定期監測水質中的抗菌素抗藥性基因，顯示環境監測解決方案存在持續的市場機會。

市場挑戰

實施和維護診斷技術所需的大量資金投入是限制抗菌素抗藥性監測市場成長的主要因素。這一成本壁壘嚴重限制了自動化報告系統的普及，尤其是在醫療預算有限、難以資金籌措數位基礎設施的地區。因此，開發中國家的許多醫療機構仍然沿用人工數據收集方法，而不是採用數位追蹤平台，這實際上限制了診斷設備製造商的潛在市場規模。

此外，難以獲得必要的預算撥款直接阻礙了全球監測網路的擴充性。當醫療機構無法承擔初始資本支出和持續營運成本時，供應商在高負擔地區的需求就會下降。世界衛生組織（世衛組織）指出，到2024年，只有11%的國家會撥出專案財政資源用於實施國家抗菌素抗藥性計畫。這種專款的匱乏導致全球潛在市場的大部分未能開發，從而阻礙了標準化監測設備的廣泛應用。

市場趨勢

全基因測序(WGS) 的廣泛應用正在革新全球抗菌藥物抗藥性監測市場，使其能夠對病原體進行超越傳統表現型方法的精準基因表徵。這項技術進步使公共衛生網路能夠快速識別感染叢集，追蹤多重抗藥性克隆的演變，並準確區分復發和再感染。隨著實驗室越來越依賴基因組數據來指南防治策略，分子診斷正成為國家監測基礎設施的標準。歐洲疾病預防控制中心 (ECDC) 2025 年 11 月發布的一份報告顯示，在 26 個國家的參與實驗室中，84% 的實驗室報告稱使用包括 PCR 和全基因組定序在內的分子方法來篩選分離株，以進行更高級的抗菌藥物敏感性測試。

同時，人工智慧 (AI) 和機器學習的融合正在徹底改變監測資料的處理和預測分析方式。這些先進的計算工具能夠分析來自各種來源的龐大而複雜的資料集，有助於及早發現新出現的抗藥性熱點，並最佳化經驗性處方實踐。透過自動識別抗藥性模式，人工智慧驅動的平台顯著縮短了產生可操作見解所需的時間，從而刺激了對智慧監測生態系統的大量投資。例如，根據 Alliance News 2025 年 11 月報道，葛蘭素史克 (GSK) 與舉措)的戰略合作夥伴關係已承諾資金籌措約 50 個科研崗位，這些崗位專注於利用先進的緩解和超級計算技術追蹤和感染疾病。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球抗菌素抗藥性監測市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依解決方案分類（診斷試劑盒、診斷系統、監控軟體、服務）
    • 按應用領域（臨床診斷、公共衛生監測、其他應用）
    • 依最終使用者（醫院/診所、研究/學術機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美抗菌素抗藥性監測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲抗菌素抗藥性監測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區抗菌素抗藥性監測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲抗菌素抗藥性監測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲抗菌素抗藥性監測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球抗菌素抗藥性監測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Luminex Corporation（DiaSorin）
  • Thermo Fisher Scientific Inc
  • Accelerate Diagnostics, Inc.
  • Liofilchem SrI
  • Becton, Dickinson, and Company
  • Biomerieux Inc.
  • Bruker Corp.
  • Danaher Corporation
  • Merck KgaA
  • Abbott Laboratories Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23856

The Global Antimicrobial Resistance Surveillance Market is projected to expand from USD 6.54 billion in 2025 to USD 9.27 billion by 2031, reflecting a compound annual growth rate of 5.98%. This sector comprises specialized diagnostic instruments and software platforms designed to systematically track and analyze how pathogens respond to antimicrobial drugs. The primary forces propelling this growth include the critical need to address the rising prevalence of multidrug-resistant organisms and the global enforcement of strict antimicrobial stewardship programs. Additionally, significant government efforts and funding aimed at bolstering laboratory infrastructure and ensuring data compatibility are actively speeding up the adoption of these essential monitoring systems within healthcare networks.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.54 Billion
Market Size 2031USD 9.27 Billion
CAGR 2026-20315.98%
Fastest Growing SegmentDiagnostic kits
Largest MarketNorth America

Despite this progress, major hurdles exist due to the high costs associated with installing and maintaining advanced surveillance technologies, which hinders adoption in resource-limited settings. This financial constraint frequently restricts the spread of automated reporting capabilities in developing regions that lack adequate technical infrastructure. According to the World Health Organization, 127 countries had formally joined the Global Antimicrobial Resistance and Use Surveillance System by 2025 to support standardized monitoring initiatives, yet the cost barrier continues to challenge universal implementation.

Market Driver

The escalating prevalence of multi-drug resistant infections acts as the main catalyst for the Global Antimicrobial Resistance Surveillance Market, creating an urgent need to expand diagnostic capabilities. As pathogens evolve to resist standard treatments more rapidly, healthcare systems are forced to implement advanced monitoring frameworks capable of detecting resistance patterns in real time. This rise in biological threats fuels the demand for high-throughput systems that support empirical therapy and containment strategies. According to The Lancet's September 2024 systematic analysis, bacterial antimicrobial resistance is forecast to cause over 39 million direct deaths globally between 2025 and 2050, compelling diagnostic developers to prioritize technologies that identify emerging resistance markers to reduce this anticipated mortality burden.

A second critical driver is the increase in public and private funding for AMR research and infrastructure, which directly addresses the high costs of building comprehensive surveillance networks. Governments and international organizations are actively financing the modernization of laboratories to bridge data gaps across human, animal, and environmental health sectors. For instance, the UK Government announced in May 2024 a financial package of £85 million to bolster international efforts, including surveillance strengthening in the Caribbean and Africa. Despite such investments, gaps remain; the Global Coalition on Aging reported in February 2024 that only four out of eleven analyzed high-income countries regularly monitored water for antimicrobial resistance genes, indicating a sustained market opportunity for environmental surveillance solutions.

Market Challenge

The significant financial investment needed to install and maintain diagnostic technologies acts as a major restraint on the antimicrobial resistance surveillance market's growth. This cost barrier severely restricts the uptake of automated reporting systems, especially in regions with limited healthcare budgets where funding digital infrastructure is difficult. As a result, many healthcare facilities in developing economies persist in using manual data collection methods instead of integrating digital tracking platforms, which effectively limits the potential market size for diagnostic manufacturers.

Furthermore, the inability to secure necessary budget allocations directly impedes the scalability of global surveillance networks. When medical institutions are unable to afford initial capital expenditures or ongoing operational costs, vendors experience reduced demand in high-burden regions. According to the World Health Organization, only 11 percent of countries had allocated dedicated financial resources to implement their national antimicrobial resistance action plans in 2024. This lack of specific financing leaves a large portion of the potential global market untapped, thereby stalling the widespread deployment of standardized monitoring instruments.

Market Trends

The widespread adoption of Whole Genome Sequencing (WGS) is significantly transforming the Global Antimicrobial Resistance Surveillance Market by allowing for precise genetic characterization of pathogens beyond traditional phenotypic methods. This technological advancement enables public health networks to quickly identify transmission clusters, track the evolution of multi-drug resistant clones, and accurately distinguish between relapse and reinfection. As laboratories increasingly rely on genomic data to guide containment strategies, molecular diagnostics are becoming a standard element of national monitoring infrastructures. According to the European Centre for Disease Prevention and Control's November 2025 report, 84 percent of participating laboratories across 26 countries reported using molecular methods, including PCR and whole-genome sequencing, to select isolates for advanced antimicrobial susceptibility testing.

Concurrently, the integration of Artificial Intelligence and Machine Learning is revolutionizing how surveillance data is processed and used for predictive analytics. These advanced computational tools analyze vast and complex datasets from various sources, facilitating the early detection of emerging resistance hotspots and the optimization of empirical prescribing practices. By automating the identification of resistance patterns, AI-driven platforms drastically reduce the time needed to generate actionable insights, attracting significant investment into smart surveillance ecosystems. For example, Alliance News reported in November 2025 that a strategic partnership between GSK and the Fleming Initiative committed £45 million to fund approximately 50 scientific roles focused on using advanced AI and supercomputing to track and mitigate drug-resistant infections.

Key Market Players

  • Luminex Corporation (DiaSorin)
  • Thermo Fisher Scientific Inc
  • Accelerate Diagnostics, Inc.
  • Liofilchem S.r.I.
  • Becton, Dickinson, and Company
  • Biomerieux Inc.
  • Bruker Corp.
  • Danaher Corporation
  • Merck KgaA
  • Abbott Laboratories Inc.

Report Scope

In this report, the Global Antimicrobial Resistance Surveillance Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antimicrobial Resistance Surveillance Market, By Solution

  • Diagnostic kits
  • Diagnostic systems
  • Surveillance software
  • Services

Antimicrobial Resistance Surveillance Market, By Application

  • Clinical Diagnostics
  • Public Health Surveillance
  • Other Applications

Antimicrobial Resistance Surveillance Market, By End User

  • Hospitals & Clinics
  • Research & Academic Institutes
  • Others

Antimicrobial Resistance Surveillance Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antimicrobial Resistance Surveillance Market.

Available Customizations:

Global Antimicrobial Resistance Surveillance Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antimicrobial Resistance Surveillance Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Solution (Diagnostic kits, Diagnostic systems, Surveillance software, Services)
    • 5.2.2. By Application (Clinical Diagnostics, Public Health Surveillance, Other Applications)
    • 5.2.3. By End User (Hospitals & Clinics, Research & Academic Institutes, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Antimicrobial Resistance Surveillance Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Solution
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antimicrobial Resistance Surveillance Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Solution
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Antimicrobial Resistance Surveillance Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Solution
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Antimicrobial Resistance Surveillance Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Solution
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Antimicrobial Resistance Surveillance Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Solution
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Antimicrobial Resistance Surveillance Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Solution
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. France Antimicrobial Resistance Surveillance Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Solution
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Antimicrobial Resistance Surveillance Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Solution
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Antimicrobial Resistance Surveillance Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Solution
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Antimicrobial Resistance Surveillance Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Solution
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia Pacific Antimicrobial Resistance Surveillance Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Solution
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Antimicrobial Resistance Surveillance Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Solution
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Antimicrobial Resistance Surveillance Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Solution
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Antimicrobial Resistance Surveillance Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Solution
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Antimicrobial Resistance Surveillance Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Solution
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Antimicrobial Resistance Surveillance Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Solution
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. Middle East & Africa Antimicrobial Resistance Surveillance Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Solution
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Antimicrobial Resistance Surveillance Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Solution
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Antimicrobial Resistance Surveillance Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Solution
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Antimicrobial Resistance Surveillance Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Solution
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. South America Antimicrobial Resistance Surveillance Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Solution
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Antimicrobial Resistance Surveillance Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Solution
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Antimicrobial Resistance Surveillance Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Solution
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Antimicrobial Resistance Surveillance Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Solution
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Antimicrobial Resistance Surveillance Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Luminex Corporation (DiaSorin)
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific Inc
  • 15.3. Accelerate Diagnostics, Inc.
  • 15.4. Liofilchem S.r.I.
  • 15.5. Becton, Dickinson, and Company
  • 15.6. Biomerieux Inc.
  • 15.7. Bruker Corp.
  • 15.8. Danaher Corporation
  • 15.9. Merck KgaA
  • 15.10. Abbott Laboratories Inc.

16. Strategic Recommendations

17. About Us & Disclaimer